Factors associated with SARS-CoV-2 infection and outcome in patients with solid tumors or hematological malignancies: a single-center study

Abstract Background Immunocompromised cancer patients are presumed to be at high risk of developing COVID-19 infection. Predisposing factors to contracting COVID-19 and to severe outcomes have been described in registries but were not compared between solid tumors and hematological malignancies. Method This retrospective single oncologic center study included adults with solid tumors or hematological malignancies referred to testing by naso-pharyngeal swab for a SARS-CoV-2 RT-PCR from March 10 to May 18, 2020. Results A total of 212 patients were included in the study. Forty-five (21%) were tested positive with SARS-CoV-2. The univariate analysis with positive SARS-CoV-2 PCR as a dependent variable reveals significant odds ratios (ORs) for age—with a mean of 62.5 years—(OR: 1.05, 95% CI: 1.02–1.08), performance status ≥2 (OR: 2.38, 95% CI: 1.22–4.70), inpatient status (OR: 2.36, 95%CI: 1.11–4.91), and hematological malignancies (OR: 2.48, 95% CI: 1.23–4.96). In contrast, OR for solid tumors reveals a negative association (OR: 0.40, 95% CI: 0.20–0.81). When integrating severe outcome (ICU admission or COVID-19-related death) as a dependent variable, the univariate logistic regression model shows significant ORs for pre-existing lymphopenia (OR: 4.0, 95% CI: 1.17–15.04), hematological malignancies (OR: 3.73, 95% CI: 1.09–13.80), and a negative association for solid tumors (OR: 0.27; 95% CI: 0.07–0.92). Conclusion In patients referred for SARS-CoV-2 testing, hematological malignancies were associated with a higher risk of COVID-19 infection and severe outcomes. Other factors were age and inpatient status.

Download Full-text

ABCL-013: Factors Associated with SARS-CoV-2 Infection and Outcome in Patients with Solid Tumors or Hematological Malignancies: A Single-Center Study

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/s2152-2650(21)01858-9 ◽

2021 ◽

Vol 21 ◽

pp. S375-S376

Author(s):

Anouk Goudsmit ◽

Edouard Cubilier ◽

Anne-Pascale Meert ◽

Philippe Aftimos ◽

Konstantinos Stathopoulos ◽

...

Keyword(s):

Solid Tumors ◽

Hematological Malignancies ◽

Single Center ◽

Factors Associated ◽

Single Center Study ◽

Center Study

Download Full-text

Poster: ABCL-013: Factors Associated with SARS-CoV-2 Infection and Outcome in Patients with Solid Tumors or Hematological Malignancies: A Single-Center Study

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/s2152-2650(21)01529-9 ◽

2021 ◽

Vol 21 ◽

pp. S243

Author(s):

Anouk Goudsmit ◽

Edouard Cubilier ◽

Anne-Pascale Meert ◽

Philippe Aftimos ◽

Konstantinos Stathopoulos ◽

...

Keyword(s):

Solid Tumors ◽

Hematological Malignancies ◽

Single Center ◽

Factors Associated ◽

Single Center Study ◽

Center Study

Download Full-text

Clinical and Molecular Findings of Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacterales in Patients with Solid Tumors: A Single-Center Study

Microbial Drug Resistance ◽

10.1089/mdr.2020.0530 ◽

2021 ◽

Author(s):

Maria Szymankiewicz ◽

Elżbieta Stefaniuk ◽

Anna Baraniak ◽

Tomasz Nowikiewicz

Keyword(s):

Solid Tumors ◽

Single Center ◽

Extended Spectrum ◽

Single Center Study ◽

Center Study

Download Full-text

Response to: Comment on “Factors Associated with Recurrent Ulcers in Patients with Gastric Surgery after More Than 15 Years: A Cross-Sectional Single-Center Study”

Gastroenterology Research and Practice ◽

10.1155/2019/9214597 ◽

2019 ◽

Vol 2019 ◽

pp. 1-2

Author(s):

Anca Negovan ◽

Monica Pantea ◽

Claudia Banescu ◽

Simona Mocan

Keyword(s):

Gastric Surgery ◽

Single Center ◽

Cross Sectional ◽

Factors Associated ◽

Single Center Study ◽

Recurrent Ulcers ◽

Center Study

Download Full-text

ALLOGENEIC CORD BLOOD TRANSPLANTATION IN CHILDREN WITH HEMATOLOGICAL MALIGNANCIES: A Long-Term Follow-Up Single-Center Study

Pediatric Hematology and Oncology ◽

10.1080/08880010902773040 ◽

2009 ◽

Vol 26 (4) ◽

pp. 165-174 ◽

Cited By ~ 10

Author(s):

Miguel A. Diaz ◽

Marta Gonzalez-Vicent ◽

Manuel Ramirez ◽

Julian Sevilla ◽

Alvaro Lassaletta ◽

...

Keyword(s):

Cord Blood ◽

Hematological Malignancies ◽

Cord Blood Transplantation ◽

Single Center ◽

Blood Transplantation ◽

Single Center Study ◽

Long Term Follow Up ◽

Center Study

Download Full-text

Mild Renal Impairment as a Potential Prognostic Factor in Patients with Solid Tumors and Hematological Malignancies.

Blood ◽

10.1182/blood.v106.11.2250.2250 ◽

2005 ◽

Vol 106 (11) ◽

pp. 2250-2250

Author(s):

Martina Kleber ◽

Kris Bauchmüller ◽

Gabriele Ihorst ◽

Bernd Koch ◽

Monika Engelhardt

Keyword(s):

Risk Factor ◽

Clinical Outcome ◽

Renal Impairment ◽

Renal Disease ◽

Solid Tumors ◽

Hematological Malignancies ◽

Heart Diseases ◽

Statistical Significance ◽

Performance Status ◽

Mild Renal Impairment

Abstract The outcome of cancer patients (pts) is influenced by a variety of coexisting conditions. Renal impairment has been shown to be one major risk factor in a number of diseases, such as myocardial infarction (MI), and is associated with dismal clinical outcome. However the influence of milder degrees of renal disease is less well defined, especially not yet in pts with solid tumors (ST) or hematological malignancies (HM). Between 8/2004-3/2005, we analyzed 167 ST and HM pts. Of 108 male and 59 female pts, 94 had ST and 73 HM. Their median age was 59 years (range; 18–91). Local vs. advanced (=metastatic) disease was present in 36 vs. 131 pts, respectively. Disease specific parameters, such as tumor diagnoses, sex, age, local vs. advanced disease, performance status (Karnofsky index=KI), number of concurrent diagnoses, cardiovascular risk factors such as body-mass index (BMI), presence of stroke or transient ischemic attack (TIA) and comorbidities (Satariano index=SI) were determined, also serum creatinine (creat), cystatin C (cC) and ProBNP (BNP). The glomerular filtration rate (GFR) was estimated by use of the ’Modification of Diet in Renal Disease’ (MDRD) equation (NEJM2004; 351:1285). The SI included heart diseases, diabetes, cancer, respiratory, gallbladder, and liver deteriorations. Pts were compared within GFR-, cC-, creat- and comorbidity-groups. Despite a median of 3 (range; 0–8) concurrent diagnoses, the KI in all pts was almost normal with a median of 90% (range; 30–100) and the median SI was 1 (range; 0–3). The median MDRD of all pts was 88ml/min/1.73m2 (14–240), and groups with GFR ≥75 (I), 60–74.9 (II), 45–59.9 (III) and <45 (IV) consisted of 105, 26, 23 and 13 pts, respectively. Of note was that pts showing a decreased GFR (<75ml/min/1.73m2) were older, had a significantly higher BMI (p=0.013), increased number of concurrent diagnoses (p=0.0486), and elevated creat- (p<0.0001), cC- (p<0.0001) and BNP-levels (p<0.0001; all Wilcoxon 2-sample tests). GFR - as compared to creat- or cC-levels - demonstrated this correlation best. Renal impairment (determined by elevated creat levels) was associated with increased odds ratios of 1.4 (95%CI 0.5–4.2), 1.5 (95%CI 0.7–3.2), 2.3 (95%CI 0.1–38.3) and 7.2 (95%CI 1.8–28.3) for comorbidities, such as diabetes, hypertension, apoplex and MI, respectively, which for the latter proved to be of statistical significance (p=0.0044). These observations indicate that grouping pts according to their renal function may be one way of determining specific risk groups. Comparing creat-, cC- and GFR-levels, the latter seems most valuable for determining mild or moderate renal impairment. Especially prior MI and elevated BNP levels will be studied further, since both seem closely associated with risks for renal impairment. Ongoing studies will determine, if mild renal disease is also a risk factor for adverse clinical outcome in ST and HM pts.

Download Full-text